About
About Jiangxi Fushine Pharmaceutical Co., Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancroid. The company also provides tazobactam, piperacillin, sultamicillin, sultamicillin tosylate, tazobactam sodium, sulbactam sodium, sulbactam pivoxil, avibactam sodium, sitafloxacin, torasemide, moxifloxacin hydrochloride, paroxetine hydrochloride, and berberine hydrochloride products. In addition, it offers lithium-ion battery electrolyte additives; and microbial protein, amino acid water-soluble fertilizer, and other bio-fermentation products. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. Jiangxi Fushine Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Jingdezhen, China.
Research context
Jiangxi Fushine Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Jiangxi Fushine Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 9.1% below its 200 day moving average.
From a valuation standpoint, the stock is 59.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
Jiangxi Fushine Pharmaceutical Co., Ltd's total revenue sank by 21.9% to $293M since the same quarter in the previous year.
Its net income has dropped by 27.0% to $74M since the same quarter in the previous year.
Finally, its free cash flow fell by 2055.8% to $-72M since the same quarter in the previous year.
Based on the above factors, Jiangxi Fushine Pharmaceutical Co., Ltd gets an overall score of 1/5.